Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen

Current Pharmaceutical Design

Volumn 18, Issue 25, 2012, Pages 3804-3811

  Vermeij, Renee ^a   Leffers, Ninke ^a   Melief, Cornelis J ^b,c   Daemen, Toos ^a   Nijman, Hans W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ISA Pharmaceuticals BV   (Netherlands)

Author keywords

Clinical trial; Epithelial ovarian cancer; Immunization; Immunotherapy; Lymphocyte; p53; Tumor antigen; Vaccine

Indexed keywords

ABAGOVOMAB; KEYHOLE LIMPET HEMOCYANIN; OREGOVOMAB; PROTEIN P53; TUMOR ANTIGEN; VIRUS VECTOR;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; OVARY CANCER; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW;

ANTIGENS; FEMALE; HUMANS; IMMUNOTHERAPY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84867511320     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802002805     Document Type: Review

References (122)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 17-6-2010.
3. du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005; 16 Suppl 8: viii7-viii12.
4. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 4-1-1996; 334: 1-6.
5. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. J Epidemiol Biostat 2001; 6: 107-38.
6. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumorinfiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 20-12-2005; 102: 18538-43.
7. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 16-1-2003; 348: 203-13.
8. Leffers N, Gooden MJ, de Jong RA, et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 2009; 58: 449-59.
9. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-9.
10. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 17-5-2001; 411: 380-4.
11. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991; 49: 281-355.
12. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 21-12-1998; 188: 2357-68.
13. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
14. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003; 9: 606-12.
15. Clarke B, Tinker AV, Lee CH, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 2009; 22: 393-402.
16. Wolf D, Wolf AM, Rumpold H, et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 112-2005; 11: 8326-31.
17. Milne K, Kobel M, Kalloger SE, et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE 2009; 4: e6412.
18. Badoual C, Hans S, Fridman WH, Brasnu D, Erdman S, Tartour E. Revisiting the prognostic value of regulatory T cells in patients with cancer. J Clin Oncol 1-7-2009; 27: e5-e6.
19. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8: 299-308.
20. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 15-10-2006; 12: 6106-15.
21. Chekmasova AA, Brentjens RJ. Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer. Discov Med 2010; 9: 62-70.
22. Chiang CL, Benencia F, Coukos G. Whole tumor antigen vaccines. Semin Immunol 2010; 22: 132-43.
23. Finn OJ. Cancer immunology. N Engl J Med 19-6-2008; 358: 2704-15.
24. Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M. HER-2/neu as a target for cancer vaccines. Immunotherapy 2010; 2: 213-26.
25. Nijman HW, Lambeck A, van der Burg SH, van der Zee AG, Daemen T. Immunologic aspect of ovarian cancer and p53 as tumor antigen. J Transl Med 15-9-2005; 3: 34.
26. Vermeij R, de Bock GH, Leffers N, et al. Tumor-infiltrating Cytotoxic T Lymphocytes as Independent Prognostic Factor in Epithelial Ovarian Cancer With Wilms Tumor Protein 1 Overexpression. J Immunother 7-6-2011.
27. Vermeij R, Daemen T, de Bock GH, et al. Potential target antigens for a universal vaccine in epithelial ovarian cancer. Clin Dev Immunol 2010; 2010.
28. Zhang S, Zhou X, Yu H, Yu Y. Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer 2010; 10: 163.
29. Odunsi K, Jungbluth AA, Stockert E, et al. NY-ESO-1 and LAGE- 1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 15-9-2003; 63: 6076-83.
30. Hu XF, Yang E, Li J, Xing PX. MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma. Expert Rev Anticancer Ther 2006; 6: 1261-71.
31. Sabbatini P, Odunsi K. Immunologic Approaches to Ovarian Cancer Treatment. J Clin Oncol 10-7-2007; 25: 2884-93.
32. Diefenbach CS, Gnjatic S, Sabbatini P, et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res 1-5-2008; 14: 2740-8.
33. Herrin V, Behrens RJ, Achtar M, et al. Wild-type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinoma. American Society of Clinical Oncology, annual meeting 660. 2003.
34. Herrin VE, Achtar MS, Steinberg SM, et al. A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide-pulsed dendritic cells in high risk ovarian cancer patients. American Society of Clinical Oncology, annual meeting 3011. 2007. g.
35. Chianese-Bullock KA, Irvin WP, Jr., et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother 2008; 31: 420-30.
36. Tsuda N, Mochizuki K, Harada M, et al. Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother 2004; 27: 60-72.
37. Nishikawa H, Qian F, Tsuji T, et al. Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination. J Immunol 15-5-2006; 176: 6340-6.
38. Odunsi K, Qian F, Matsuzaki J, et al. Vaccination with an NYESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences 31-7-2007; 104: 12837-42.
39. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008; 8: 351-60.
40. Kenter GG, Welters MJ, Valentijn AR, et al. Phase I immunotherapeutic trial with long peptides spanning the e6 and e7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 1-1-2008; 14: 169-77.
41. Welters MJ, Kenter GG, Piersma SJ, et al. Induction of tumorspecific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 1-1-2008; 14: 178-87.
42. Speetjens FM, Kuppen PJK, Welters MJP, et al. Induction of p53- specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res 2009; 15: 1086-95.
43. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 5-11-2009; 361: 1838-47.
44. Leffers N, Lambeck AJ, Gooden MJ, et al. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer 28-5-2009; 125: 2104-13.
45. van der Burg SH, Bijker MS, Welters MJP, Offringa R, Melief CJM. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Advanced Drug Delivery Reviews 1-10-2006; 58: 916-30.
46. Shackleton M, Davis ID, Hopkins W, et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun 2004 Sep 23; 4: 9. 9.
47. Toes RE, Blom RJ, Offringa R, Kast WM, Melief CJ. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol 15-5-1996; 156: 3911-3918.
48. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 1- 11-2000; 96: 3102-8.
49. Bennett SR, Carbone FR, Toy T, Miller JF, Heath WR. B cells directly tolerize CD8(+) T cells. J Exp Med 7-12-1998; 188: 1977-83.
50. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, van der Burg SH, Offringa R. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol 2008; 38: 1033-42.
51. Toes RE, van der Voort EI, Schoenberger SP, et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol 1-5-1998; 160: 4449-56.
52. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol 15-10-2007; 179: 5033-40.
53. Kessler JH, Melief CJ. Identification of T-cell epitopes for cancer immunotherapy. Leukemia 2007; 21: 1859-74.
54. Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007; 220: 129-50.
55. Van Driessche A, Van der Velde AL, Nijs G, et al. Cytotherapy.2009; 11(5): 653-68.
56. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 1-11-2000; 96: 3102-8.
57. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 29-7-2010; 363: 411-22.
58. Odunsi K, Rodabaugh K, Lele S, et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY-ESO-1 efficiently induces antibody, CD4+ and CD8+ anti tumor immune responses in patients with ovarian cancer. 2007. 1-1-2007.
59. Gulley JL, Arlen PM, Tsang KY, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 15-5-2008; 14: 3060-9.
60. Mohebtash M, Madan R, Tsang K, Arlen Ph, Pazdur M, Jones J, Gulley J. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. 2009. 2009.
61. Freedman RS, Kudelka AP, Verschraegen CF, et al. Therapeutic anti-cancer vaccine: a randomized doule blind dose comparison study of sialyl Tn-KLH with Detox-B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). 1998. 1998.
62. MacLean GD, Bowen-Yacyshyn MB, Samuel J, et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J Immunother (1991) 1992; 11: 292-305.
63. MacLean GD, Reddish MA, Koganty RR, Longenecker BM. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol 1996; 19: 59-68.
64. Sabbatini PJ, Kudryashov V, Ragupathi G, et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Int J Cancer 1-7-2000; 87: 79-85.
65. Sabbatini PJ, Ragupathi G, Hood C, et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res 15-7-2007; 13: 4170-7.
66. Sandmaier BM, Oparin DV, Holmberg LA, Reddish MA, MacLean GD, Longenecker BM. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after highdose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J Immunother 1999; 22: 5466.
67. Wagner U. Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma 1993; 12: 521-8.
68. Wagner U, Reinsberg J, Schmidt S, et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophys 1994; 24-25: 237-42.
69. Oei AL, Sweep FC, Thomas CM, Boerman OC, Massuger LF. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review). Int J Oncol 2008; 32: 1145-57.
70. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol 1994; 15: 42-52.
71. Pfisterer J, du Bois A, Sehouli J, et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol 2006; 17: 1568-77.
72. Reinartz S, Kohler S, Schlebusch H, et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 1-3-2004; 10: 1580-7.
73. Sabbatini P, Dupont J, Aghajanian C, et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 15-9-2006; 12: 5503-10.
74. Berek JS, Ehlen TG, Gordon A, et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. 2001.
75. Berek JS, Taylor PT, Gordon A, et al. Randomized, placebocontrolled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 1-9- 2004; 22: 3507-16.
76. Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 20-1- 2009; 27: 418-25.
77. Braly P, Nicodemus CF, Chu C, et al. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother 2009; 32: 54-65.
78. Ehlen TG, Hoskins PJ, Miller D, et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer 2005; 15: 1023-34.
79. Gordon AN, Schultes BC, Gallion H, et al. CA125- and tumorspecific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol 2004; 94: 340-51.
80. Schultes BC, Baum RP, Niesen A, Noujaim AA, Madiyalakan R. Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunol Immunother 1998; 46: 201-12.
81. Nicholson S, Bomphray CC, Thomas H, McIndoe A, Barton D, Gore M, George AJ. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol Immunother 2004; 53: 809-16.
82. Strohlein MA, Siegel R, Jager M, Lindhofer H, Jauch KW, Heiss MM. Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 2009; 28: 18.
83. Zanten-Przybysz I, Molthoff C, Gebbinck JK, et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. J Cancer Res Clin Oncol 2002; 128: 484-92.
84. Berek JS, Taylor PT, Nicodemus CF. CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5- year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. J Immunother 2008; 31: 207-14.
85. Sabbatini P, Berek JS, Casado A, et al. Abagovomab maintenance therapy in patients with epithelial ovarian cacner after complete response (CR) post-first-line chemotherapy (FLCT): Preliminary results of the randomized, double-blind, placebo-controlled, multicenter MIMOSA trial. J Clinical Oncol 28[15s (Suppl; abstract 5036)]. 2010.
86. Croci DO, Zacarias Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG: Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 2007; 56: 1687-700.
87. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-74.
88. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 6-10-2008; 27: 5904-12.
89. Begley J, Ribas A. Targeted therapies to improve tumor immunotherapy. Clin Cancer Res 15-7-2008; 14: 4385-91.
90. Chianese-Bullock KA, Lewis ST, Sherman NE, Shannon JD, Slingluff CL, Jr. Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies. Vaccine 10-3-2009; 27: 1764-70.
91. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 16-11-2000; 408: 307-10.
92. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
93. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-99.
94. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 5-7-1991; 253: 49-53.
95. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 15-9-1994; 54: 4855-78.
96. de Vries A, Flores ER, Miranda B, et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci USA 5-3-2002; 99: 2948-53.
97. Melief CJ, Offringa R, Toes RE, Kast WM. Peptide-based cancer vaccines. Curr Opin Immunol 1996; 8: 651-7.
98. Vierboom MP, Nijman HW, Offringa R, et al. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 29- 8-1997; 186: 695-704.
99. Zwaveling S, Vierboom MP, Ferreira Mota SC, et al. Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. Cancer Res 1-11-2002; 62: 6187-93.
100. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
101. Olsson T. Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 1995; 144: 245-68.
102. Houbiers JG, Nijman HW, van der Burg SH, et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993; 23: 2072-7.
103. Asai T, Storkus WJ, Mueller-Berghaus J, et al. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins. Cancer Immun 16-4- 2002; 2: 3.
104. Chikamatsu K, Albers A, Stanson J, et al. P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res 1-7- 2003; 63: 3675-81.
105. van der Burg SH, de Cock K, Menon AG, et al. Long lasting p53specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. Eur J Immunol 2001; 31: 146-55.
106. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 15-8-1994; 58: 480-7.
107. Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, Wild CP. p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Clin Cancer Res 1995; 1: 1463-.
108. Lauwen MM, Zwaveling S, de Quartel L, et al. Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen. Cancer Res 1-2-2008; 68: 893-900.
109. Rahma O, Achtar M, Czystowska C, et al. Comparable effect of p53 peptide vaccine in adjuvant or pulsed on denritic cells in ovarian cancer patients: A gynecologic oncology group study. American Association for Cancer research, annual meeting 2010. 19-4- 2010.
110. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma 1. N Engl J Med 30-9-2010; 363: 1324-34.
111. Conroy H, Marshall NA, Mills KH. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 7-1-2008; 27: 168-80.
112. Buckanovich RJ, Facciabene A, Kim S, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008; 14: 28-36.
113. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008; 5: 194-204.
114. Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 1-6-2008; 14: 3536-44.
115. Laheru D, Lutz E, Burke J, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 1-3-2008; 14: 1455-63.
116. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 15-4-2003; 100: 4712-4717.
117. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 26-2-2008; 105: 3005-10.
118. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma 1. N Engl J Med 19-8-2010; 363: 711-23.
119. Chu CS, Boyer J, Coukos G, et al. Autologous denritic cell (IDD- 6) vaccination as consolidation for advanced ovarian cancer. 2008.
120. Britten CM, Gouttefangeas C, Welters MJ, et al. The CIMTmonitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother 2008; 57: 289-302.
121. Hoos A, Eggermont AM, Janetski S, et al. J Natl Cancer Inst. 2010; 102(18): 1388-97.
122. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-81.